Literature DB >> 2051274

Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease.

J S Hyams1, W R Treem, E Eddy, N Wyzga, R E Moore.   

Abstract

Chronic undernutrition and high-dose daily corticosteroid therapy are well-accepted causes of growth failure in children with inflammatory bowel disease. Occasionally, children are seen with minimal gastrointestinal symptoms but in whom severe anorexia and profound growth impairment are evident. Recent observations that elevated serum levels of tumor necrosis factor-alpha (TNF) in cachexia associated with a number of disease states have suggested a similar possible role in inflammatory bowel disease. Accordingly, we determined TNF levels in 45 children and adolescents with inflammatory bowel disease (18 ulcerative colitis, 27 Crohn's disease) at varying times during their clinical course and compared them to values obtained from a group of 25 children with functional bowel disease. No differences were noted in serum TNF levels between the children with inflammatory bowel disease and the control population. Values were generally within the range of the lower limit of detection of the assay. In the children with inflammatory bowel disease, there was no significant correlation between TNF levels and disease activity or growth parameters. Our observations suggest that elevated TNF levels are not associated with inflammatory bowel disease in children.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2051274     DOI: 10.1097/00005176-199102000-00016

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  14 in total

1.  Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.

Authors:  J Bauditz; J Haemling; M Ortner; H Lochs; A Raedler; S Schreiber
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 2.  Molecular pathways driving disease-specific alterations of intestinal epithelial cells.

Authors:  Rocío López-Posadas; Markus F Neurath; Imke Atreya
Journal:  Cell Mol Life Sci       Date:  2016-09-13       Impact factor: 9.261

3.  Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease.

Authors:  M Noguchi; N Hiwatashi; Z Liu; T Toyota
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

4.  Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies.

Authors:  S Dionne; J Hiscott; I D'Agata; A Duhaime; E G Seidman
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

6.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.

Authors:  H C Reinecker; M Steffen; T Witthoeft; I Pflueger; S Schreiber; R P MacDermott; A Raedler
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

7.  Systemic tumor necrosis factor-alpha production in experimental colitis.

Authors:  D R Mack; A S Lau; P M Sherman
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

8.  Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease.

Authors:  J S Hyams; J E Fitzgerald; N Wyzga; W R Treem; C J Justinich; D L Kreutzer
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

9.  Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis.

Authors:  Didia Bismara Cury; Sender Jankiel Mizsputen; Clara Versolato; Luciana Odashiro Miiji; Edson Pereira; Maria Aparecida Delboni; Nestor Schor; Alan C Moss
Journal:  Cell Immunol       Date:  2013-04-23       Impact factor: 4.868

10.  Plasma-induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment-naive paediatric inflammatory bowel disease.

Authors:  B Gurram; N H Salzman; M L Kaldunski; S Jia; B U K Li; M Stephens; M R Sood; M J Hessner
Journal:  Clin Exp Immunol       Date:  2016-01-29       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.